47045-SWZ-T-NERCHA-1 The Global Fund to Fight AIDS, Tuberculosis and Malaria <narrative>Tuberculosis - Eswatini (01-Oct-2011-30-Jun-2015)</narrative> Eswatini, Tuberculosis, National Emergency Response Council on HIV and AIDS The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS National Emergency Response Council on HIV and AIDS The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria Communications +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS, Tuberculosis and Malaria Grant Management Division Marion Gleixner Fund Portfolio Manager +41 58 791 1700 marion.gleixner@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Eswatini Tuberculosis Ensure healthy lives and promote well-being for all at all ages End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases 6343.00 Global Fund disbursement to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 50000.00 Global Fund disbursement to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 2330886.55 Global Fund disbursement to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 3491691.00 Global Fund disbursement to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 12234286.55 Global Fund commitment to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 493357.00 Global Fund disbursement to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 25000.00 Global Fund disbursement to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 704460.00 Global Fund commitment to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS -5837009.00 Global Fund commitment to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 518347.00 Global Fund disbursement to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS -186113.00 Global Fund commitment to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 476743.00 Global Fund commitment to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 476743.00 Global Fund disbursement to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS -14578.38 Global Fund commitment to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 14578.38 Funds returned to the Global Fund from SWZ-T-NERCHAP01. National Emergency Response Council on HIV and AIDS The Global Fund to Fight AIDS, Tuberculosis and Malaria 402576.71 Funds returned to the Global Fund from SWZ-T-NERCHAP01. National Emergency Response Council on HIV and AIDS The Global Fund to Fight AIDS, Tuberculosis and Malaria -402576.71 Global Fund commitment to SWZ-T-NERCHAP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS <narrative>Grant page on the data explorer of the Global Fund.</narrative> An overview of a grant over its lifetime. <narrative>Grant terms and conditions.</narrative> General terms and conditions which apply to Global Fund grants. 47045-SWZ-T-NERCHA-2 The Global Fund to Fight AIDS, Tuberculosis and Malaria <narrative>Expand access to high quality DOTS; address TB/HIV co-infections and emergency response to the challenge of MDR-TB - Eswatini (01-Jul-2015-30-Sep-2018)</narrative> Eswatini, Tuberculosis, National Emergency Response Council on HIV and AIDS Goal: Accelerated reduction of TB in Swaziland. Objectives: To implement and expand country-wide collaborative TB/HIV activities and management of co-morbidities by 2019; To increase TB case detection rates from 46% in 2013 to 70% in 2017 and 80% by 2019; To increase TB treatment success rates for all bacteriologically confirmed cases from 72.9% in 2013 to 90% by 2019; To provide treatment and support to all drug-resistant TB cases and reduce the MDR-TB prevalence rate amongst new TB cases to less than 5% by 2019; To strengthen the capacity of the National Tuberculosis Control Program to effectively implement, coordinate and evaluate TB prevention, treatment and care interventions. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS National Emergency Response Council on HIV and AIDS The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria Communications +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS, Tuberculosis and Malaria Grant Management Division Marion Gleixner Fund Portfolio Manager +41 58 791 1700 marion.gleixner@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Eswatini Tuberculosis Ensure healthy lives and promote well-being for all at all ages End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases 9676133.00 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 1046479.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 15000.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 2586886.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 841691.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 10000.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 5084661.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS -91416.00 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 8917766.00 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 3794739.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 4151353.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 25000.00 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 25000.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 25000.00 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS -971674.00 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 5593881.00 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 5563881.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 25000.00 Global Fund disbursement to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS -30000.00 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS 81410.44 Funds returned to the Global Fund from SWZ-T-NERCHAP02. National Emergency Response Council on HIV and AIDS The Global Fund to Fight AIDS, Tuberculosis and Malaria -81410.44 Global Fund commitment to SWZ-T-NERCHAP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria National Emergency Response Council on HIV and AIDS <narrative>Grant page on the data explorer of the Global Fund.</narrative> An overview of a grant over its lifetime. <narrative>Grant terms and conditions.</narrative> General terms and conditions which apply to Global Fund grants. <narrative>MDR TB-Other 1: Percentage of MDR patient who convert to negetaive during intensive treatment phase( interim outcome)</narrative> Module: MDR-TB. <narrative>MDR TB-Other 1: Percentage of MDR patient who convert to negetaive during intensive treatment phase( interim outcome)</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 97; Denominator: 191. Numerator: 128; Denominator: 213. Numerator: 128; Denominator: 213. Numerator: 67; Denominator: 159. Numerator: 189; Denominator: 290. Numerator: 189; Denominator: 290. Numerator: 86; Denominator: 126. Numerator: 279; Denominator: 398. Numerator: 84; Denominator: 109. Numerator: 222; Denominator: 277. Numerator: 107; Denominator: 146. <narrative>Number of TB cases with RR-TB and/or MDR-TB notified</narrative> Module: MDR-TB. <narrative>Number of TB cases with RR-TB and/or MDR-TB notified</narrative> Geographic coverage: National. Aggregation: Non cumulative. <narrative>Number of cases with RR-TB and/or MDR-TB that began second-line treatment</narrative> Module: MDR-TB. <narrative>Number of cases with RR-TB and/or MDR-TB that began second-line treatment</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 465; Denominator: 465; Percentage: 100%. Numerator: 213. Numerator: 154. Numerator: 290. Numerator: 118. Numerator: 290. Numerator: 398. Numerator: 104. Numerator: 398. Numerator: 92. Numerator: 277. Numerator: 113. <narrative>Percentage of DST laboratories showing adequate performance on External Quality Assurance</narrative> Module: MDR-TB. <narrative>Percentage of DST laboratories showing adequate performance on External Quality Assurance</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 1; Denominator: 1; Percentage: 100%. Numerator: 1. Numerator: 1. Numerator: 1. Numerator: 1. Numerator: 1. Numerator: 1. Numerator: 1. Numerator: 1. Numerator: 1; Denominator: 1; Percentage: 100%. Numerator: 1. Numerator: 1. <narrative>Percentage of cases with RR-TB and/or MDR-TB started on treatment for MDR-TB who were lost to follow up during the first six months of treatment</narrative> Module: MDR-TB. <narrative>Percentage of cases with RR-TB and/or MDR-TB started on treatment for MDR-TB who were lost to follow up during the first six months of treatment</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 23; Denominator: 106; Percentage: 22%. Numerator: 32; Denominator: 213; Percentage: 15%. Numerator: 6. Numerator: 23; Denominator: 213; Percentage: 10.8%. Numerator: 0; Denominator: 159; Percentage: 0%. Numerator: 50; Denominator: 290; Percentage: 17.2%. Numerator: 23; Denominator: 290; Percentage: 7.9%. Numerator: 0; Denominator: 125; Percentage: 0%. Numerator: 32; Denominator: 398; Percentage: 8%. Numerator: 2; Denominator: 109; Percentage: 1.8%. Numerator: 9; Denominator: 208; Percentage: 4.3%. Numerator: 0; Denominator: 146; Percentage: 0%. <narrative>Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)</narrative> Module: MDR-TB. <narrative>Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 630; Denominator: 670; Percentage: 94%. Numerator: 371; Denominator: 390; Percentage: 95.1%. Numerator: 466; Denominator: 491; Percentage: 94.9%. Numerator: 466; Denominator: 491; Percentage: 94.9%. Numerator: 560; Denominator: 589; Percentage: 95.1%. Numerator: 560; Denominator: 589; Percentage: 95.1%. Numerator: 0. Numerator: 684; Denominator: 698; Percentage: 98%. Numerator: 0. <narrative>Number of TB cases (all forms) notified among key affected populations/high risk groups</narrative> Module: TB care and prevention. <narrative>Number of TB cases (all forms) notified among key affected populations/high risk groups</narrative> Geographic coverage: National. Aggregation: Non cumulative. <narrative>Number of notified cases of all forms of TB (i.e. bacteriologically confirmed + clinically diagnosed), new and relapse cases</narrative> Module: TB care and prevention. <narrative>Number of notified cases of all forms of TB (i.e. bacteriologically confirmed + clinically diagnosed), new and relapse cases</narrative> Geographic coverage: National. Aggregation: Non cumulative. <narrative>Number of notified cases of bacteriologically confirmed TB, new and relapses</narrative> Module: TB care and prevention. <narrative>Number of notified cases of bacteriologically confirmed TB, new and relapses</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 3748; Denominator: 5582; Percentage: 67.1%. Numerator: 2737; Denominator: 3421; Percentage: 80%. Numerator: 1261. Numerator: 3405; Denominator: 4256; Percentage: 80%. Numerator: 1119; Denominator: 1884; Percentage: 59.4%. Numerator: 3405. Numerator: 4037; Denominator: 5058; Percentage: 79.8%. Numerator: 943; Denominator: 1533; Percentage: 61.5%. Numerator: 4037; Denominator: 5058; Percentage: 79.8%. Numerator: 1047. Numerator: 2318. Numerator: 1291. <narrative>Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period</narrative> Module: TB care and prevention. <narrative>Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 2197; Denominator: 2794; Percentage: 78.6%. Numerator: 1831; Denominator: 2233; Percentage: 82%. Numerator: 1086. Numerator: 2326; Denominator: 2737; Percentage: 85%. Numerator: 1018; Denominator: 1230; Percentage: 82.8%. Numerator: 2326; Denominator: 2737; Percentage: 85%. Numerator: 2996; Denominator: 3405; Percentage: 88%. Numerator: 875; Denominator: 1040; Percentage: 84.1%. Numerator: 2996; Denominator: 3405; Percentage: 88%. Numerator: 1038; Denominator: 1173; Percentage: 88.5%. Numerator: 2086; Denominator: 2318; Percentage: 90%. Numerator: 1356; Denominator: 1525; Percentage: 88.9%. <narrative>Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period</narrative> Module: TB care and prevention. <narrative>Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 24; Denominator: 26; Percentage: 92.3%. Numerator: 24; Denominator: 26; Percentage: 92.3%. Numerator: 22. Numerator: 26; Denominator: 30; Percentage: 86.7%. Numerator: 23; Denominator: 24; Percentage: 95.8%. Numerator: 30; Denominator: 35; Percentage: 85.7%. Numerator: 33; Denominator: 35; Percentage: 94.3%. Numerator: 21; Denominator: 24; Percentage: 87.5%. Numerator: 38; Denominator: 40; Percentage: 95%. Numerator: 24; Denominator: 28; Percentage: 85.7%. Numerator: 40; Denominator: 40; Percentage: 100%. Numerator: 27; Denominator: 27; Percentage: 100%. <narrative>Percentage of reporting units reporting no stock-outs of anti-TB drugs on the last day of the quarter</narrative> Module: TB care and prevention. <narrative>Percentage of reporting units reporting no stock-outs of anti-TB drugs on the last day of the quarter</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 86; Denominator: 86; Percentage: 100%. Numerator: 86; Denominator: 86; Percentage: 100%. Numerator: 78. Numerator: 96; Denominator: 96; Percentage: 100%. Numerator: 80; Denominator: 105; Percentage: 76.2%. Numerator: 96; Denominator: 96; Percentage: 100%. Numerator: 111; Denominator: 111; Percentage: 100%. Numerator: 98; Denominator: 102; Percentage: 96.1%. Numerator: 123; Denominator: 123; Percentage: 100%. Numerator: 111; Denominator: 125; Percentage: 88.8%. Numerator: 123; Denominator: 123; Percentage: 100%. Numerator: 92; Denominator: 114; Percentage: 80.7%. <narrative>Treatment success rate- all forms: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period, new and relapse cases</narrative> Module: TB care and prevention. <narrative>Treatment success rate- all forms: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period, new and relapse cases</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 5012; Denominator: 6647; Percentage: 75.4%. Numerator: 1916; Denominator: 2456; Percentage: 78%. Numerator: 1936. Numerator: 2438; Denominator: 3010; Percentage: 81%. Numerator: 1759; Denominator: 2228; Percentage: 79%. Numerator: 2438; Denominator: 3010; Percentage: 81%. Numerator: 3146; Denominator: 3745; Percentage: 84%. Numerator: 1421; Denominator: 1756; Percentage: 80.9%. Numerator: 3146; Denominator: 3745; Percentage: 84%. Numerator: 1559; Denominator: 1831; Percentage: 85.1%. Numerator: 2549; Denominator: 2897; Percentage: 88%. Numerator: 2073; Denominator: 2420; Percentage: 85.7%. <narrative>Percentage of HIV-positive registered TB patients given anti-retroviral therapy during TB treatment</narrative> Module: TB/HIV. <narrative>Percentage of HIV-positive registered TB patients given anti-retroviral therapy during TB treatment</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 3123; Denominator: 3972; Percentage: 78.6%. Numerator: 1986; Denominator: 2422; Percentage: 82%. Numerator: 1478. Numerator: 2482; Denominator: 2920; Percentage: 85%. Numerator: 1223; Denominator: 1341; Percentage: 91.2%. Numerator: 2482; Denominator: 2920; Percentage: 85%. Numerator: 3019; Denominator: 3355; Percentage: 90%. Numerator: 939; Denominator: 1015; Percentage: 92.5%. Numerator: 3019; Denominator: 3355; Percentage: 90%. Numerator: 1108; Denominator: 1163; Percentage: 95.3%. Numerator: 1797; Denominator: 1892; Percentage: 95%. Numerator: 1312; Denominator: 1345; Percentage: 97.5%. <narrative>Percentage of TB patients who had an HIV test result recorded in the TB register</narrative> Module: TB/HIV. <narrative>Percentage of TB patients who had an HIV test result recorded in the TB register</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 5430; Denominator: 5582; Percentage: 97.3%. Numerator: 3318; Denominator: 3421; Percentage: 97%. Numerator: 2215. Numerator: 4171; Denominator: 4256; Percentage: 98%. Numerator: 1867; Denominator: 1884; Percentage: 99.1%. Numerator: 4171; Denominator: 4256; Percentage: 98%. Numerator: 5007; Denominator: 5058; Percentage: 99%. Numerator: 1479; Denominator: 1533; Percentage: 96.5%. Numerator: 5007; Denominator: 5058; Percentage: 99%. Numerator: 1663; Denominator: 1675; Percentage: 99.3%. Numerator: 5877; Denominator: 5936; Percentage: 99%. Numerator: 2053; Denominator: 2073; Percentage: 99%. <narrative>TB/HIV-other 1:Percentage of TB patients initiated on CPT</narrative> Module: TB/HIV. <narrative>TB/HIV-other 1:Percentage of TB patients initiated on CPT</narrative> Geographic coverage: National. Aggregation: Non cumulative. Numerator: 3904; Denominator: 3972. Numerator: 2374; Denominator: 2422. Numerator: 2862; Denominator: 2920. Numerator: 1327; Denominator: 1341. Numerator: 2862; Denominator: 2920. Numerator: 3321; Denominator: 3355. Numerator: 1015; Denominator: 1015. Numerator: 3321; Denominator: 3355. Numerator: 1161; Denominator: 1163. Numerator: 1874; Denominator: 1892. Numerator: 1340; Denominator: 1345.